Emergent Biosolutions Inc.

EBS Healthcare Drug Manufacturers Specialty & Generic

Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.

6.38 0.80 −11.14%
Market cap
$368.1M
P/E
0.0×
Fwd P/E
−26.5×
Dividend yield
—
F-score
6/9
Altman Z
1.63
Beneish M
−3.56
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
13.01 0.00 0.00 0.00 10.04 15.50 50.90 47.42 24.60 28.90
Piotroski F-Score
6 6 3 3 6 7 7 2 7 4
P/S ratio
0.89 0.49 0.13 0.54 1.31 3.04 2.51 3.80 3.57 2.73
Altman Z-Score
1.63 0.99 (0.67) 0.70 2.84 3.70 2.48 2.40 9.16 3.85
P/FCF ratio
3.39 11.59 0.00 0.00 24.20 11.95 27.48 0.00 13.08 0.00
Altman Z″-Score (non-manufacturers)
3.44 1.59 (2.03) 1.18 5.09 4.74 3.17 2.92 10.24 5.99
Beneish M-Score
(3.56) (3.46) (3.70) (2.98) (2.46) (2.93) (2.71) (1.96) (2.35) (2.45)
P/Operating CF
8.51 (6.34) 4.13 6.49 7.09 19.27 22.76 (17.91) 25.88 (105.59)
P/B ratio
1.27 1.05 0.20 0.43 1.44 3.26 2.55 2.94 2.20 2.24
Price to Tangible BV
7.68 0.00 1.60 1.37 2.95 9.13 25.49 0.00 2.70 2.56
EV/Sales
1.38 1.02 0.84 1.22 1.46 3.20 3.09 4.67 3.28 2.69
EV/EBITDA
4.98 142.08 0.00 0.00 5.07 9.03 15.02 23.89 10.92 9.15
EV/Operating CF
6.01 18.15 (4.27) (40.04) 8.09 9.29 18.20 87.37 8.85 24.08
EV/FCF
5.26 24.38 (3.42) (9.11) 26.95 12.61 33.85 (131.85) 12.01 (60.88)
Quick Ratio
2.22 1.60 0.46 0.65 2.28 2.22 2.03 1.91 3.25 3.97
Current Ratio
5.01 3.69 1.04 0.98 3.40 3.11 3.17 3.10 4.85 4.82
Net Debt/EBITDA
1.76 74.41 (2.07) (48.00) 0.52 0.47 2.82 4.46 (0.98) (0.02)
Debt/Assets
43.39% 47.76% 47.18% 44.40% 28.42% 30.52% 34.86% 35.64% 1.26% 27.64%
Debt/Equity
1.09 1.37 1.32 1.01 0.52 0.61 0.75 0.79 0.01 0.45
Asset Turnover
0.55 0.65 0.42 0.36 0.61 0.60 0.49 0.47 0.55 0.49
Operating CF/Net income
3.24 (0.31) 0.27 0.16 1.46 1.76 3.45 0.67 2.52 1.05
Capex/Depreciation
0.23 (0.13) (0.14) (0.89) (1.32) (1.19) (0.76) (1.10) (1.24) (1.99)
Interest Coverage
1.69 (1.53) (8.26) (4.56) 9.90 13.86 2.97 9.07 18.83 13.88
ROE
10.46% (33.67%) (74.67%) (14.08%) 14.32% 24.07% 5.19% 6.52% 10.95% 8.25%
ROA
3.88% (11.86%) (30.48%) (6.91%) 7.51% 11.71% 2.39% 3.80% 8.10% 5.16%
ROIC
7.06% (6.53%) (32.48%) (4.94%) 11.33% 15.90% 4.12% 3.31% 10.41% 11.12%
Return on Tangible Assets
7.15% (26.96%) (185.04%) (26.48%) 12.92% 20.96% 5.38% 6.74% 10.42% 6.63%
Average Days of Receivables
41.37 54.04 66.44 52.00 56.53 54.18 89.34 126.47 95.07 110.87
Research and Development Expense of Revenue
7.16% 6.77% 10.62% 16.85% 13.26% 15.08% 20.45% 18.25% 17.36% 21.87%
Selling, General and Administrative Expense of Revenue
25.05% 29.51% 35.11% 30.38% 19.66% 19.50% 24.73% 25.88% 25.48% 29.28%
Intangible Assets out of Total Assets
0.33 0.36 0.31 0.30 0.28 0.32 0.42 0.46 0.16 0.08
Share Based Compensation of Revenue
2.18% 1.72% 2.20% 4.04% 2.39% 3.28% 2.41% 2.97% 2.71% 3.78%
Graham Net Nets
(0.20) (0.61) (3.73) (0.94) (0.03) (0.05) (0.20) (0.20) 0.16 0.10
Graham Number
14.45 0.00 0.00 0.00 54.30 59.76 22.45 23.82 30.94 19.59
Earnings Yield
7.69% (37.97%) (572.59%) (33.25%) 9.96% 6.45% 1.96% 2.11% 4.07% 3.46%
Free Cash Flow Yield
29.49% 8.62% (194.48%) (24.89%) 4.13% 8.37% 3.64% (0.93%) 7.65% (1.62%)
Revenue per Share
13.89 19.69 20.49 22.31 33.15 29.51 21.48 15.62 13.42 12.16
Operating CF per Share
3.19 1.11 (4.03) (0.68) 5.99 10.17 3.65 0.83 4.98 1.36
Capex per Share
0.46 (0.28) (1.01) (2.75) (4.19) (2.68) (1.69) (1.39) (1.31) (1.90)
Free Cash Flow per Share
3.64 0.82 (5.04) (3.43) 1.80 7.50 1.96 (0.55) 3.67 (0.54)
Cash per Share
3.91 1.99 2.18 12.83 10.77 11.79 3.26 2.24 4.29 6.75
Shareholders Equity per Share
9.77 9.11 12.68 27.70 30.26 27.46 21.14 20.18 21.83 14.83
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
9.77 9.11 12.68 27.70 30.26 27.46 21.14 20.18 21.83 14.83
Free Cash Flow
195.00 43.70 (257.90) (171.70) 96.10 395.00 101.10 (27.70) 153.30 (21.60)
Working Capital
530.30 436.30 28.20 (18.50) 898.30 811.40 469.90 420.40 385.30 404.36
Capital Expenditures
24.40 (15.00) (51.60) (137.60) (224.10) (141.00) (86.90) (69.50) (54.80) (76.20)
Net Current Asset Value
(133.50) (308.20) (494.40) (568.20) (67.90) (240.30) (552.60) (597.70) 327.50 136.31
EV/EBIT
10.24 0.00 0.00 0.00 7.59 11.48 29.99 40.67 14.82 12.46
Capex to Sales
(0.03) 0.01 0.05 0.12 0.13 0.09 0.08 0.09 0.10 0.16
Price to Operating Income
6.61 0.00 0.00 0.00 6.81 10.89 24.35 33.07 16.13 12.66
Other line items
Depreciation/Fixed assets
0.51 0.43 0.95 0.19 0.21 0.18 0.21 0.12 0.11 0.10
Cash ROIC
14.96% 3.49% (15.91%) (5.00%) 3.17% 13.40% 4.89% (1.44%) 13.87% (1.90%)
Accounts Receivable Turnover
6.22 6.04 5.99 5.15 7.02 6.20 4.08 3.75 3.81 3.63
Accounts Payable Turnover
5.60 7.87 6.54 5.96 5.65 4.54 4.94 5.26 4.91 3.48
Inventory Turnover
1.00 2.13 2.08 1.98 2.27 1.98 2.02 1.85 1.73 1.87
Average Days of Payables
62.21 32.63 58.06 54.51 62.89 94.80 79.82 91.39 81.28 100.13
Days of Inventory on Hand
384.25 166.99 170.19 184.69 171.16 213.85 187.34 233.07 277.69 213.86
Average Receivables
119.35 172.75 175.10 216.95 252.80 250.80 270.90 208.60 147.29 134.48
Average Payables
58.25 86.55 107.85 116.20 132.50 115.45 87.75 61.25 38.22 36.31
Average Inventory
327.55 320.30 339.80 350.75 328.90 264.75 214.15 174.30 108.40 67.44
Average Assets
1,354.15 1,606.45 2,494.75 3,062.65 2,921.10 2,605.25 2,278.35 1,649.80 1,020.16 1,003.80
Average Common Equity
502.70 566.05 1,018.50 1,503.35 1,533.00 1,267.75 1,049.70 961.60 754.25 628.11

Fold the line items

Columns are period end dates